A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

Project: Other project

Project Details

StatusActive
Effective start/end date1/29/211/28/26

Funding

  • Merck Sharp & Dohme Corporation: $6,346.15